Prostate Cancer – NCI-07-C-0059
Dr. William L. Dahut
Principal Investigator
NCI is currently conducting the following trial for patients with prostate cancer. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Dahut and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
A Phase II Study of AZD2171 in Metastatic Androgen-Independent Prostate Cancer
NCI-07-C-0059
- Patients receive oral AZD2171 in addition to prednisone once daily on Days 1–28
- Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
- Blood samples are collected at baseline and periodically during Course 1 of study therapy
- Patients undergo a dynamic contrast-enhanced MRI at baseline and on Days 2, 28, 56, after Cycle 4, and then every four cycles
Why is this trial important?
There are no proven therapies in patients who have progressed after docetaxel chemotherapy for metastatic prostate cancer. Angiogenesis has been shown to play an important role in prostate cancer progression. VEGF is implicated in tumor blood vessel formation and in disease progression. Anti-angiogenic therapy directed at the VEGF signaling pathway may be helpful in advanced prostate cancer. Cediranib, AZD2171, an orally available small molecule, is a potent inhibitor of receptor tyrosine kinases that influence VEGF and has been shown to inhibit VEGF signaling. This trial will look at the anti-tumor activity of cediranib in patients with metastatic prostate cancer post docetaxel.
Back to Top
